MAPT and Alzheimer disease: However, two studies comprising of largely AD dementia patients investigated the relationship between [18F]flortaucipir retention and pathological tau burden and found that a minimum neuropathological Braak stage of IV was necessary to visually detect an elevated AD [18F]flortaucipir PET signal [29, 69].